Published • loading... • Updated
AbbVie Inc. (ABBV) Stock: Surge as VRAYLAR Data Strengthens Mood Disorder Treatment Case
Summary by Blockonomi
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
AbbVie Inc. (ABBV) Stock: Surge as VRAYLAR Data Strengthens Mood Disorder Treatment Case
TLDR AbbVie shares rise as VRAYLAR data strengthens its mood disorder treatment case. VRAYLAR real-world studies show gains in depression symptoms and daily function. Bipolar I patients recorded better symptoms, functioning, and quality of life. AbbVie expands VRAYLAR evidence with pediatric safety and comparative research. Patient survey results support adjunctive treatment after weak antidepressant response. [...]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
